TTWM
GSK icon

TCV Trust & Wealth Management’s GSK GSK Stock Holding History

TCV Trust & Wealth Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,800
Closed -$282K – 175
2019
Q4 		$282K Sell
4,800
-106,698
-96% -$5.94M 0.03% 167
2019
Q3 		$5.95M Buy
111,498
+1,192
+1% +$61.3K 0.77% 43
2019
Q2 		$5.52M Buy
110,306
+2,593
+2% +$130K 0.72% 46
2019
Q1 		$5.63M Sell
107,713
-1,021
-0.9% -$51K 0.74% 45
2018
Q4 		$5.19M Sell
108,734
-5,772
-5% -$284K 0.76% 43
2018
Q3 		$5.75M Sell
114,506
-3,258
-3% -$166K 0.77% 45
2018
Q2 		$5.93M Sell
117,764
-184
-0.2% -$9.27K 0.83% 41
2018
Q1 		$5.76M Sell
117,948
-2,272
-2% -$106K 0.83% 45
2017
Q4 		$5.33M Sell
120,220
-9,266
-7% -$428K 0.74% 49
2017
Q3 		$6.57M Sell
129,486
-4,864
-4% -$247K 0.97% 42
2017
Q2 		$7.24M Sell
134,350
-1,300
-1% -$69.3K 1.09% 34
2017
Q1 		$7.15M Buy
135,650
+2,944
+2% +$149K 1.09% 35
2016
Q4 		$6.39M Buy
132,706
+2,600
+2% +$128K 1.04% 38
2016
Q3 		$7.01M Buy
130,106
+4,389
+3% +$241K 1.19% 34
2016
Q2 		$6.81M Buy
125,717
+11,300
+10% +$595K 1.18% 31
2016
Q1 		$5.8M Buy
114,417
+19,571
+21% +$975K 1.04% 37
2015
Q4 		$4.78M Buy
94,846
+1,898
+2% +$96.7K 0.85% 42
2015
Q3 		$4.47M Buy
92,948
+4,765
+5% +$248K 0.81% 45
2015
Q2 		$4.59M Buy
88,183
+2,656
+3% +$150K 0.75% 46
2015
Q1 		$4.93M Buy
85,527
+1,781
+2% +$102K 0.8% 42
2014
Q4 		$4.47M Buy
83,746
+3,501
+4% +$196K 0.74% 45
2014
Q3 		$4.61M Buy
80,245
+3,821
+5% +$234K 0.78% 42
2014
Q2 		$5.11M Buy
76,424
+3,374
+5% +$228K 0.84% 41
2014
Q1 		$4.88M Buy
73,050
+2,999
+4% +$203K 0.82% 41
2013
Q4 		$4.67M Sell
70,051
-1,941
-3% -$126K 0.8% 43
2013
Q3 		$4.51M Sell
71,992
-17,718
-20% -$1.14M 0.88% 38
2013
Q2 		$5.6M Buy
+89,710
New +$5.69M 1.15% 25

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

TCV Trust & Wealth Management's GSK Position: Q1 2020 in Review

TCV Trust & Wealth Management sold out of GSK (GSK) in Q1 2020, closing a stake of 4,800 shares — an estimated $282K sold.

TCV Trust & Wealth Management first reported a position in GSK in Q2 2013 and held it in 27 quarters. The position peaked at $7.24M in Q2 2017. 817 funds tracked by Wall St. Rank hold GSK as of Q1 2020.

  • TCV Trust & Wealth Management reported no remaining GSK position as of Q1 2020 after selling out during the quarter.
  • TCV Trust & Wealth Management sold 4,800 GSK shares in Q1 2020, an estimated $282K.
  • TCV Trust & Wealth Management first reported a position in GSK in Q2 2013 and held it in 27 quarters.
  • TCV Trust & Wealth Management's GSK position peaked at $7.24M in Q2 2017.
  • 817 funds tracked by Wall St. Rank held GSK as of Q1 2020.

Based on TCV Trust & Wealth Management's 13F filing for Q1 2020, filed 8 May 2020.